Vault Nanoparticle Immunotherapy for Lung Cancer
Abstract
The object of this research is to develop a therapeutic strategy against lung cancer by utilizing novel vault bioparticles to deliver CCL21, an immunotherapeutic chemokine. Our hypothesis is that delivering CCL21 to the tumor, will make the entire repertoire of tumor antigens available in situ and thus increase the likelihood of an immune response and reduce the potential of phenotypic modulation. We have developed a bioparticle to deliver CCL21 that is based on the human vault particle. Vaults needed for initial animal studies (CCL21-vaults and empty control vaults) have been purified. We have secured ACURO approval for our animal studies and initial anti-tumor efficacy studies have been initiated in three animal models of lung cancer with the CCL21-vault as monotherapy. One model showed significant efficacy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2021
- Accession Number
- AD1149958
Entities
People
- Leonard H. Rome
Organizations
- University of California, Los Angeles